Time filter

Source Type

San Donato Milanese, Italy

Sciacca P.,University of Catania | Betta P.,University of Catania | Mattia C.,University of Catania | Volti G.L.,University of Catania | And 4 more authors.
Frontiers in Bioscience - Elite

The aim of this study was: echocardiographical assessment of cardiac alterations in late-preterm newborns with hypoxic respiratory failure (HRF), and, study serum pentraxin-3 (PTX-3) in relation to the severity of respiratory impairment and to some echocardiographic parameters (i.e. ejection fraction (EF), stroke volume (SV) and cardiac output (CO). We enrolled in this study 40 newborn infants whose 22 (group I) with moderate HRF and 18 (group II) with severe HRF. In group I the mean values of EF, SV and CO were significantly higher than in the group II. Our results showed a significant increase of PTX-3 in group II patients at 24h of life when compared to group I. Taking patients all together (n=40), we found a significant (R=-73) reverse correlation between EF and serum values of PTX-3. PTX-3 in our patients with HRF is affected by the severity of the hypoxic insult and correlate with the cardio-vascular impairment. Source

Risso F.M.,NICU G. Gaslini Childrens Hospital | Sannia A.,NICU G. Gaslini Childrens Hospital | Gazzolo D.,C. Arrigo Childrens Hospital | Gazzolo D.,nato Milanese University Hospital
Journal of Maternal-Fetal and Neonatal Medicine

The present overview is aimed at reporting the standard primary investigations that are mandatory in preterm and term newborns at admission to neonatal unit in the first hours after birth. Herein, the main neonatal screening tests for early detection of metabolic diseases are described as well as laboratory standard procedures (glycaemia, bilirubin, blood gas, infectious diseases analyses) monitoring parameters (vital signs recordings, blood and transcutaneous gas assessment, blood pressure recordings) and ultrasound pattern (cranial and cardiac). © 2012 Informa UK, Ltd. Source

Risso F.M.,slini Childrens University Hospital | Sannia A.,slini Childrens University Hospital | Gavilanes D.A.W.,Maastricht University | Vles H.J.,Maastricht University | And 6 more authors.
Journal of Maternal-Fetal and Neonatal Medicine

Objective: There is growing evidence on the usefulness of biomarkers in the early detection of preterm infants at risk for brain damage. However, among different tools Activin A, S100B protein and adrenomedullin assessment offer the possibility to investigate brain/multiorgan function and development. This could be especially useful in perinatal medicine that requires even more non-invasive techniques in order to fulfill the minimal handling in diagnostic and therapeutic strategy performance. Materials and methods: The concept of Unconventional Biological Fluid (UBF: urine and saliva) is becoming even stronger and regards the assessment in non-invasive biological fluids of biochemical markers involved in the cascade of events leading to brain damage. Results: Activin A, S100B protein and adrenomedullin in UBF were increased in preterm newborns developing brain damage and/or ominous outcome. Conclusions: The present manuscript offers an update on the usefulness of Activin A, S100B protein an adrenomedullin in UBF as brain damage markers. The findings open a new cue on the use of these markers in daily neonatal intensive care unit (NICU) activities. © 2012 Informa UK, Ltd. Source

Florio P.,University of Siena | Frigiola A.,nato Milanese University Hospital | Battista R.,University of Siena | El Hadi Abdalla A.,University of Siena | And 7 more authors.
Frontiers in Bioscience - Elite

Activin-A is a protein over-expressed and secreted by the brain after neuronal destruction. We evaluated whether serum activin-A increases in asphyxiated full-term newborns (AFTNs) at risk of hypoxic-ischemicencephalopathy (HIE). 105 consecutive infants (35 affected by perinatal asphyxia due to acute fetal distress; 70 healthy gestational-age matched newborns) underwent cranial assessment and neurologic examination at 12, 24 and 72 hours after birth and, on discharge from the hospital and; activin-A and monitoring laboratory variables assessment at birth. According to the occurrence of HIE within 7-days after birth, AFTNs were subdivided in Group A (n= 20; no/mild HIE with good prognosis) and Group B (n= 15; moderate/severe HIE with a greater risk of neurological handicap). Activin-A was significantly (P less than 0.0001) higher in Groups A and B than controls and highest (P less than 0.001) in Group B. At 0.66 ng/L activin-A achieved a sensitivity of 93.33% and a specificity of 96.63%, respectively, as HIE diagnostic test. These findings show that activin A increased in AFTNs with HIE before the appearance of related signs. Source

Sannia A.,University of Genoa | Risso F.M.,University of Genoa | Serpero L.D.,University of Genoa | Frulio R.,University of Genoa | And 5 more authors.
Clinica Chimica Acta

Background: Maternal glucocorticoid (GC) treatment is widely used to prevent lung immaturity in preterm infants. There is growing evidence that GCs may be detrimental to the Central Nervous System (CNS). We investigated whether antenatal GC administration affects CNS function in a dose-dependent manner by measuring urine concentrations of a well-established brain damage marker, S100B. Methods: We conducted a case-control-study in 70 preterm infants (1 GC vs 1 control) whose mothers received a complete GC-course (GC2, n=16), half-course (GC1, n=19), and controls (n=35). At four predetermined time-points, in the first 72. h from birth, we assessed S100B urine concentrations, using a commercially available immunoluminometric assay (Lia-mat Sangtec 100, AB Sangtec Medical, Bromma, Sweden). Data were correlated with primary neonatal outcomes (incidence of respiratory distress syndrome, length of ventilatory support and hospital stay, incidence of intraventricular hemorrhage, adverse 7th day neurological follow-up and neonatal death). Results: S100B in GC2 group at all monitoring time-points was significantly lower (P <0.01) than controls and GC1 group, while no differences (P >0.05) were evident between controls and GC1 group. No significant differences (P >0.05) were shown in primary outcomes between half or complete GC-course treated groups. Conclusion: S100B levels of infants antenatally treated with GCs differed in a dose-dependent manner. Data on primary outcomes suggest that lowering antenatal GC-course may be less detrimental for brain without affecting lung maturation. Further clinical trials are needed to elucidate the low GC-course issue. © 2010 Elsevier B.V. Source

Discover hidden collaborations